Two Sigma Investments’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Two Sigma Investments’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-48,835	Closed	-$181K	–	3779
2017 Q4	$181K	Buy	+48,835	New	+$200K	﹤0.01%	2945
2015 Q3	–	Sell	-12,173	Closed	-$273K	–	3029
2015 Q2	$273K	Buy	+12,173	New	+$193K	﹤0.01%	2478
2015 Q1	–	Sell	-4,114	Closed	-$47K	–	3003
2014 Q4	$47K	Buy	+4,114	New	+$44.7K	﹤0.01%	2164

Two Sigma Investments's CASC Position: Q1 2018 in Review

Two Sigma Investments sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 48,835 shares — an estimated $181K sold.

Two Sigma Investments first reported a position in CASC in Q4 2014 and held it in 3 quarters. The position peaked at $273K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Two Sigma Investments reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Two Sigma Investments sold 48,835 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $181K.
Two Sigma Investments first reported a position in Cascadian Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
Two Sigma Investments's Cascadian Therapeutics, Inc. position peaked at $273K in Q2 2015.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Two Sigma Investments's 13F filing for Q1 2018, filed 15 May 2018.